Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875916 | 0.83 | P2RX7 (0.46) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL14107962 | 0.81 | CYP2A6 (0.47) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL8667094 | 0.80 | P2RX7 (0.59) | KCNH2HTR2AP2RX7ALDH1A1LMNA | |
| SCHEMBL7773063 | 0.79 | ALDH1A1 (0.43) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL320376 | 0.78 | LOXL2 (0.50) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL8303374 | 0.77 | KCNH2 (0.51) | KCNH2HTR2ASLC6A4SLC6A3LOXL2 | |
| SCHEMBL15561990 | 0.77 | ALDH1A1 (0.45) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL12653174 | 0.77 | ALDH1A1 (0.42) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL533946 | 0.77 | ALDH1A1 (0.42) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 | |
| SCHEMBL2678910 | 0.77 | LOXL2 (0.47) | KCNH2HTR2ASLC6A4SLC6A3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | KCNH2 4507/4885HTR2A 1857/4885SLC6A4 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.